Your browser doesn't support javascript.
loading
Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
Hendershott, Taylor R; Zhu, Delphine; Llanes, Seoni; Zabetian, Cyrus P; Quinn, Joseph; Edwards, Karen L; Leverenz, James B; Montine, Thomas; Cholerton, Brenna; Poston, Kathleen L.
Afiliação
  • Hendershott TR; Department of Psychological and Brain Sciences, Washington University, St. Louis, Missouri, USA.
  • Zhu D; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Llanes S; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Zabetian CP; Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.
  • Quinn J; Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Edwards KL; Department of Neurology, Oregon Health Sciences University, Portland, Oregon, USA.
  • Leverenz JB; Department of Epidemiology, University of California, Irvine School of Medicine, Irvine, California, USA.
  • Montine T; Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Cholerton B; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.
  • Poston KL; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Mov Disord ; 34(2): 285-291, 2019 02.
Article em En | MEDLINE | ID: mdl-30776152
ABSTRACT

BACKGROUND:

Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD.

METHODS:

The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521).

RESULTS:

The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%).

CONCLUSION:

The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD. © 2018 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtornos Cognitivos / Disfunção Cognitiva / Testes de Estado Mental e Demência Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mov Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Transtornos Cognitivos / Disfunção Cognitiva / Testes de Estado Mental e Demência Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mov Disord Assunto da revista: NEUROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos